Gyre Current Deferred Revenue vs Total Liab Analysis

GYRE Stock

11.98 0.20 1.70%

Gyre Therapeutics financial indicator trend analysis is much more than just examining Gyre Therapeutics latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Gyre Therapeutics is a good investment. Please check the relationship between Gyre Therapeutics Current Deferred Revenue and its Total Liab accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Gyre Stock refer to our How to Trade Gyre Stock guide.

Current Deferred Revenue vs Total Liab

Current Deferred Revenue vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Gyre Therapeutics Current Deferred Revenue account and Total Liab. At this time, the significance of the direction appears to have strong relationship.

The correlation between Gyre Therapeutics' Current Deferred Revenue and Total Liab is 0.63. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Total Liab in the same time period over historical financial statements of Gyre Therapeutics, assuming nothing else is changed. The correlation between historical values of Gyre Therapeutics' Current Deferred Revenue and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Gyre Therapeutics are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Current Deferred Revenue i.e., Gyre Therapeutics' Current Deferred Revenue and Total Liab go up and down completely randomly.

Correlation Coefficient

0.63

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Gyre Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Gyre Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Gyre Stock refer to our How to Trade Gyre Stock guide.At present, Gyre Therapeutics' Enterprise Value is projected to increase significantly based on the last few years of reporting.

	2022	2023	2024	2025 (projected)
Depreciation And Amortization	1.1M	1.1M	1.0M	740.7K
Cost Of Revenue	798K	4.6M	5.3M	7.7M

Depreciation And Amortization Cost Of Revenue

Gyre Therapeutics fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Common Stock Shares Outstanding	Other Stockholder Equity	Short Long Term Debt Total	Net Debt	Non Current Liabilities Total	Total Liab	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Current Deferred Revenue	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Inventory	Other Current Assets	Total Current Assets	Short Term Debt	Common Stock	Intangible Assets	Short Term Investments	Non Currrent Assets Other
Total Assets		0.72	0.02	-0.1	0.42	-0.2	-0.88	-0.05	0.44	0.59	0.53	0.22	0.66	0.09	0.77	0.18	0.81	0.07	-0.69	0.67	0.91	-0.21	0.36	-0.4	0.64	0.33
Total Stockholder Equity	0.72		-0.4	-0.61	0.86	0.04	-0.71	-0.53	-0.02	-0.02	0.26	-0.46	0.51	0.3	0.64	-0.48	0.93	-0.33	-0.45	0.45	0.87	0.03	-0.25	0.07	0.79	-0.05
Retained Earnings	0.02	-0.4		0.1	-0.66	0.02	0.29	0.08	0.04	0.19	0.05	0.55	-0.05	-0.48	-0.08	0.55	-0.26	0.1	0.04	-0.05	-0.13	0.01	0.23	-0.25	-0.25	0.65
Common Stock Shares Outstanding	-0.1	-0.61	0.1		-0.61	-0.4	0.02	0.9	0.39	0.62	-0.07	0.78	-0.25	-0.26	-0.28	0.79	-0.52	0.76	0.15	-0.19	-0.41	-0.39	0.82	-0.41	-0.43	0.1
Other Stockholder Equity	0.42	0.86	-0.66	-0.61		0.05	-0.54	-0.65	-0.23	-0.24	0.07	-0.56	0.32	0.6	0.42	-0.58	0.72	-0.45	-0.26	0.26	0.6	0.05	-0.37	0.36	0.64	-0.1
Short Long Term Debt Total	-0.2	0.04	0.02	-0.4	0.05		0.26	-0.35	-0.15	-0.48	0.02	-0.31	-0.16	-0.26	-0.11	-0.27	-0.14	-0.49	0.32	-0.12	-0.13	1.0	-0.3	0.52	-0.13	-0.05
Net Debt	-0.88	-0.71	0.29	0.02	-0.54	0.26		-0.04	-0.35	-0.47	-0.37	-0.12	-0.55	-0.18	-0.85	-0.09	-0.8	0.02	0.65	-0.62	-0.84	0.25	-0.38	0.44	-0.54	-0.11
Non Current Liabilities Total	-0.05	-0.53	0.08	0.9	-0.65	-0.35	-0.04		0.53	0.63	0.05	0.62	-0.12	-0.42	-0.13	0.63	-0.39	0.7	0.01	-0.04	-0.26	-0.33	0.71	-0.57	-0.36	-0.15
Total Liab	0.44	-0.02	0.04	0.39	-0.23	-0.15	-0.35	0.53		0.69	0.87	0.36	0.63	-0.02	0.29	0.31	0.06	0.34	-0.68	0.71	0.31	-0.14	0.39	-0.4	0.08	-0.07
Other Current Liab	0.59	-0.02	0.19	0.62	-0.24	-0.48	-0.47	0.63	0.69		0.45	0.72	0.32	-0.14	0.23	0.7	0.13	0.58	-0.44	0.38	0.31	-0.47	0.79	-0.61	0.13	0.31
Total Current Liabilities	0.53	0.26	0.05	-0.07	0.07	0.02	-0.37	0.05	0.87	0.45		0.08	0.82	0.22	0.43	0.01	0.29	-0.01	-0.81	0.87	0.52	0.01	0.05	-0.17	0.29	0.02
Property Plant And Equipment Net	0.22	-0.46	0.55	0.78	-0.56	-0.31	-0.12	0.62	0.36	0.72	0.08		-0.11	-0.28	-0.04	1.0	-0.32	0.55	0.0	-0.03	-0.15	-0.3	0.91	-0.45	-0.33	0.66
Current Deferred Revenue	0.66	0.51	-0.05	-0.25	0.32	-0.16	-0.55	-0.12	0.63	0.32	0.82	-0.11		0.28	0.59	-0.17	0.59	0.04	-0.94	0.94	0.73	-0.18	-0.11	-0.14	0.7	-0.03
Accounts Payable	0.09	0.3	-0.48	-0.26	0.6	-0.26	-0.18	-0.42	-0.02	-0.14	0.22	-0.28	0.28		0.17	-0.33	0.24	-0.23	-0.27	0.22	0.21	-0.27	-0.28	0.33	0.27	0.0
Cash	0.77	0.64	-0.08	-0.28	0.42	-0.11	-0.85	-0.13	0.29	0.23	0.43	-0.04	0.59	0.17		-0.08	0.81	-0.29	-0.69	0.69	0.85	-0.11	0.13	-0.51	0.44	0.08
Non Current Assets Total	0.18	-0.48	0.55	0.79	-0.58	-0.27	-0.09	0.63	0.31	0.7	0.01	1.0	-0.17	-0.33	-0.08		-0.35	0.56	0.06	-0.09	-0.19	-0.26	0.91	-0.42	-0.34	0.65
Cash And Short Term Investments	0.81	0.93	-0.26	-0.52	0.72	-0.14	-0.8	-0.39	0.06	0.13	0.29	-0.32	0.59	0.24	0.81	-0.35		-0.24	-0.58	0.55	0.95	-0.15	-0.13	-0.23	0.79	-0.02
Net Receivables	0.07	-0.33	0.1	0.76	-0.45	-0.49	0.02	0.7	0.34	0.58	-0.01	0.55	0.04	-0.23	-0.29	0.56	-0.24		0.03	-0.1	-0.17	-0.49	0.55	-0.3	0.07	0.02
Inventory	-0.69	-0.45	0.04	0.15	-0.26	0.32	0.65	0.01	-0.68	-0.44	-0.81	0.0	-0.94	-0.27	-0.69	0.06	-0.58	0.03		-0.98	-0.72	0.33	-0.03	0.36	-0.55	0.01
Other Current Assets	0.67	0.45	-0.05	-0.19	0.26	-0.12	-0.62	-0.04	0.71	0.38	0.87	-0.03	0.94	0.22	0.69	-0.09	0.55	-0.1	-0.98		0.71	-0.13	0.0	-0.27	0.52	-0.02
Total Current Assets	0.91	0.87	-0.13	-0.41	0.6	-0.13	-0.84	-0.26	0.31	0.31	0.52	-0.15	0.73	0.21	0.85	-0.19	0.95	-0.17	-0.72	0.71		-0.14	0.0	-0.29	0.76	0.1
Short Term Debt	-0.21	0.03	0.01	-0.39	0.05	1.0	0.25	-0.33	-0.14	-0.47	0.01	-0.3	-0.18	-0.27	-0.11	-0.26	-0.15	-0.49	0.33	-0.13	-0.14		-0.29	0.5	-0.16	-0.06
Common Stock	0.36	-0.25	0.23	0.82	-0.37	-0.3	-0.38	0.71	0.39	0.79	0.05	0.91	-0.11	-0.28	0.13	0.91	-0.13	0.55	-0.03	0.0	0.0	-0.29		-0.55	-0.24	0.46
Intangible Assets	-0.4	0.07	-0.25	-0.41	0.36	0.52	0.44	-0.57	-0.4	-0.61	-0.17	-0.45	-0.14	0.33	-0.51	-0.42	-0.23	-0.3	0.36	-0.27	-0.29	0.5	-0.55		0.11	-0.01
Short Term Investments	0.64	0.79	-0.25	-0.43	0.64	-0.13	-0.54	-0.36	0.08	0.13	0.29	-0.33	0.7	0.27	0.44	-0.34	0.79	0.07	-0.55	0.52	0.76	-0.16	-0.24	0.11		-0.04
Non Currrent Assets Other	0.33	-0.05	0.65	0.1	-0.1	-0.05	-0.11	-0.15	-0.07	0.31	0.02	0.66	-0.03	0.0	0.08	0.65	-0.02	0.02	0.01	-0.02	0.1	-0.06	0.46	-0.01	-0.04

Click cells to compare fundamentals

Gyre Therapeutics Account Relationship Matchups

Gyre Therapeutics fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	94.8M	55.7M	28.4M	116.5M	134.0M	116.9M
Total Stockholder Equity	76.1M	41.1M	(21.7M)	(15.8M)	(18.2M)	(17.3M)
Retained Earnings	(314.8M)	(402.7M)	(410.9M)	(85.5M)	(77.0M)	(80.8M)
Common Stock Shares Outstanding	19.2M	30.6M	75.7M	65.8M	75.7M	79.5M
Liabilities And Stockholders Equity	94.8M	55.7M	28.4M	116.5M	134.0M	116.9M
Other Stockholder Equity	390.8M	443.8M	32.8M	3.7M	4.2M	4.0M
Short Long Term Debt Total	1.6M	2.4M	38K	409K	470.4K	446.8K
Net Debt	(28.7M)	(42.0M)	(21.6M)	(33.1M)	(38.1M)	(40.0M)
Non Current Liabilities Total	981K	408K	33.3M	18.0M	16.2M	28.6M
Total Liab	18.8M	14.6M	50.1M	38.1M	34.3M	45.0M
Other Current Liab	9.2M	236.0K	9.5M	14.3M	16.5M	17.3M
Total Current Liabilities	17.8M	14.2M	16.8M	20.0M	18.0M	20.9M
Property Plant And Equipment Net	2.3M	3.7M	70K	23.8M	27.3M	28.7M
Current Deferred Revenue	2.0M	230K	167K	79K	71.1K	67.5K
Accounts Payable	5.9M	6.4M	122K	355K	408.3K	387.8K
Cash	30.4M	44.3M	21.7M	33.5M	30.2M	40.2M
Non Current Assets Total	5.3M	4.2M	238K	59.3M	68.2M	71.6M
Cash And Short Term Investments	79.4M	46.9M	21.7M	33.5M	30.2M	28.7M
Net Receivables	3.3M	1.8M	17.1M	16.8M	15.2M	12.7M
Other Current Assets	6.8M	2.8M	2.7M	2.6M	2.3M	2.2M
Total Current Assets	89.5M	51.5M	28.2M	57.2M	51.5M	88.0M
Short Term Debt	663K	2.5M	492K	210K	241.5K	229.4K
Common Stock	22K	31K	37K	77K	88.6K	93.0K
Accumulated Other Comprehensive Income	5K	40.2M	2.3M	1.5M	1.7M	1.8M
Short Term Investments	61.5M	49.0M	2.5M	10.6M	9.5M	9.1M
Non Currrent Assets Other	528K	472K	(11.6M)	5.7M	5.1M	5.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CSX	CSX Corporation
ETON	Eton Pharmaceuticals
ALLT	Allot Communications

When determining whether Gyre Therapeutics is a strong investment it is important to analyze Gyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gyre Therapeutics' future performance. For an informed investment choice regarding Gyre Stock, refer to the following important reports:

How To Invest In Gyre

Details

Is Gyre Stock a good investment?

Details

What is Gyre Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Gyre Stock refer to our How to Trade Gyre Stock guide.

You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gyre Therapeutics. If investors know Gyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.74)

Earnings Share

(1.04)

Revenue Per Share

1.285

Quarterly Revenue Growth

(0.20)

Return On Assets

0.1018

The market value of Gyre Therapeutics is measured differently than its book value, which is the value of Gyre that is recorded on the company's balance sheet. Investors also form their own opinion of Gyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Gyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gyre Therapeutics' market value can be influenced by many factors that don't directly affect Gyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Gyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Gyre Current Deferred Revenue vs Total Liab Analysis

Current Deferred Revenue vs Total Liab

Current Deferred Revenue vs Total Liab Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Total Liab

Gyre Therapeutics fundamental ratios Correlations

Gyre Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Gyre Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Term Debt	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 0.95	Cash And Short Term Investments
Other Current Assets	+ 0.94	Current Deferred Revenue
Cash And Short Term Investments	+ 0.93	Total Stockholder Equity
Total Current Assets	+ 0.91	Total Assets

Other Current Assets	- 0.98	Inventory
Inventory	- 0.94	Current Deferred Revenue
Net Debt	- 0.88	Total Assets
Cash	- 0.85	Net Debt
Total Current Assets	- 0.84	Net Debt
Inventory	- 0.81	Total Current Liabilities